Company
AnaCardio
Private, Solna, Sweden-based clinical-stage biotech spun out of Karolinska Institutet heart-failure research. Developing AC01, an oral ghrelin-receptor agonist for heart failure with reduced ejection fraction.
1 story
Regulatory News has published 1 story about AnaCardio on 1 October 2026, sourced to the primary record — the regulator’s decision, the company’s filing or its own announcement. This page is generated from that coverage. Last updated 1 October 2026.
This page is generated from Regulatory News’ editorial coverage of AnaCardio. It is not an advertisement.
On the record
- Company
- AnaCardio AB (privately held)
- Headquarters
- Solna, Sweden, on the Karolinska Institutet campus
- Founded
- 2017; operational launch in 2021 with a licensing agreement for AC01 from Helsinn
- Latest milestone
- €62.5 million Series B financing, AC01
Each line is taken from the most recent story of ours that states it.
Products in our coverage
Our coverage
